Category: pyridine-derivatives

Bernstein, Jack; Stearns, Barbara; Shaw, Elliott; Lott, W. A. published an article in 1947, the title of the article was Derivatives of 2,6-diaminopyridine.Related Products of 51566-22-4 And the article contains the following content:

Since 2,6-diaminopyridine (I) showed an appreciable antiparasitic activity when tested against Plasmodium lophurae in ducklings, various derivatives of I have been prepared to determine if further substitution in the mol. would increase the antiparasitic activity of the parent compound I (66 g.) in 300 cc. dioxane, treated dropwise with 23.5 g. AcCl in 50 cc. dioxane (0.5 h.) at 25-30° and stirred 2 addnl. hrs., gives 40% of the 2-Ac derivative (II), m. 156-7°; 2-butyryl derivative m. 152-3°, 25%; 2-salicyloyl derivative (prepared from o-AcOC6H4COCl and purified by precipitation from dilute HCl with dilute NaOH) m. 178-9°, 44%; 2-[phenyl(acetoxy)acetyl] derivative (as HCl salt with 1 mol. H2O) m. 151-3°, 23%. N,N’-Bis(6-amino-2-pyridyl)adipamide m. 228-9°, 72%; N,N’-bis(6-amino-2-pyridyl)sebacamide m. 152-5°, 55%. 1,3-Bis(6-amino-2-pyridyl)urea does not melt, 71%. (CH2CO)2O (30 g.) in 200 cc. dioxane, treated slowly with 33 g. I in 200 cc. dioxane and heated 3 h. on the steam bath, gives 57% N-(6-amino-2-pyridyl)succinamic acid, m. 174-5° (decomposition). I (46 g.) and 222 cc. AcCH2CO2Et, heated 15 min. at 160° and the product in EtOH treated with alc. HCl, give 40% 2,6-bis(acetylacetamido)pyridine-HCl, m. 195-8°; the filtrate yields 10% of the 2-acetylacetamido derivative, m. 146-7°. I (22 g.) and 22.6 g. NCCH2CO2Et, heated 2 h. at 165°, give 85% 2-amino-6-cyanoacetamidopyridine, m. 152-3°. 2-Acetamido-6-carbethoxyacetamidopyridine m. 150-1.5°, 41%. I (282 g.) and 290 g. HOCH2CO2H, fused 15 h. at 120° under reduced pressure, give 35% 2,6-bis(glycolylamino)pyridine, m. 220-1°. I (33 g.) in 200 cc. absolute EtOH containing 6.9 g. Na and 43 g. Et2NCH2CO2Et, refluxed 2 h., give 55% 2,6-bis(diethylaminoacetamido)pyridine, m. 109.5-10.5°. I (22 g.) and 27 g. AcNHCOCl, ground in a mortar and 35 cc. C5H5N added, give 19% 2,6-bis(acetamidoacetamido)pyridine, m. 260-1°. MeC(:NH)NH2.HCl (24.6 g.) in 100 cc. absolute EtOH, added to 22 g. I in 150 cc. absolute EtOH, stirred 3 h., and allowed to stand overnight at room temperature, give 38% N-(6-amino-2-pyridyl)acetamidine-HCl, m. 246-7° (decomposition). I (396 g.) in 8 l. H2O, treated dropwise with 195 g. ClCO2Et (3 h.), gives 76% 2-amino-6-carbethoxyaminopyridine (III), m. 109-12°. I (33 g.) in 500 cc. H2O, 200 cc. N HCl, and 300 g. ice, treated dropwise with 33 g. ClCO2Et, stirred 2 h., 200 cc. N HCl added, and the mixture allowed to stand overnight at 10°, gives 55% 2,6-bis(carbethoxyamino)pyridine, m. 132.5-3.5°, and 12 g. III. III (21.6 g.) in 120 cc. 3 N EtOH-NH3, heated 12 h. at 110°, gives 75% 2-amino-6-ureidopyridine, m. 175-6° (decomposition). I (48 g.) and 48 g. CO(NH2)2, heated 36 h. at 130°, give 49% 2,6-diureidopyridine, does not melt below 300° (purified by extraction with 300 cc. 3% HCl and crystallization of the residue from H2O). I (12 g.) in 1500 cc. C6H6, treated dropwise with 17.9 g. p-EtOC6H4NCO in 75 cc. C6H6, gives 86% 2-(p-ethoxyphenylureido)-6-aminopyridine, m. 168-9°; 2-(2-nitro-4-methoxyphenylureido)-6-aminopyridine m. 208-10°, 73%; reduction over Pt oxide gives 50% of the corresponding 2-(2-amino-4-methylphenylureido) derivative, m. 182-4°. I (154 g.) and 200 g. of the HCl salt of I, heated 12 h. at 190°, give 60% bis(6-amino-2-pyridyl)amine, m. 172-3° (the HCl salt does not melt). 2,6-Dibromopyridine (IV) (38 g.) and 160 cc. 25% aqueous MeNH2, heated 8 h. at 190°, give 59% 2,6-bis(methylamino)pyridine, m. 70-1°; this results in 20% yield from 27.6 g. 2-amino-6-bromopyridine (V) and 110 cc. 25% aqueous MeNH2 on heating 30 h. at 190°. V (80 g.) and 200 cc. EtNH2, heated 36 h. at 170-80°, give 81% 2-amino-6-(diethylamino)pyridine (VI), b4.5 122-3°, m. 34-5° (HCl salt, m. 143-4°). IV (45 g.) and 27.8 g. Et2NH in 100 cc. absolute EtOH, heated 8 h. at 170-80°, give 85% 2-bromo-6-(diethylamino)pyridine (VII), b4 97-9°; VII does not react with NH4OH (d. 0.9) at 170-80° (8 h.); 11 g. VII and 35 cc. 5 N EtOH-NH3, heated 25 h. at 170°, also did not react; 18.8 g. VII in 100 cc. NH4OH (d. 0.9) containing 1 g. CuSO4.5H2O, heated 30 h. at 140-5°, gives 44% VI. IV (35.6 g.) and 100 cc. Et2NH containing 4 cc. 25% CuSO4.5H2O, heated 30 h. at 160°, give 76% 2,6-bis(diethylamino)pyridine, b3 120-2° (HCl salt, m. 120-2°). 2-Amino-6-(3-diethylaminopropylamino)pyridine-HCl m. 65-75°, 53%; 2-acetamido-6-(4-diethylamino-1-methylbutylamino)pyridine m. 106-8° (51%). 2-Acetamido-6-(3-keto-1-methylbutylideneamino)-pyridine, 2,6-AcNHC5H3N(N:CMeCH2Ac), m. 146-7.5°, 40%. 2-Acetamido-6-(2,5-dimethyl-1-pyrryl)pyridine m. 147.5-8.5°, 54%. 2-Methoxy-6,9-dichloroacridine (11.2 g.) in 50 g. PhOH, warmed on the steam bath, treated with 11 g. I, and heated 3 h., gives 61% 2-methoxy-6-chloro-9-(6-amino-2-pyridylamino)acridine, yellow, m. 232-3°. II (30.2 g.), added in small portions to 100 cc. HNO3 (d. 1.5) at -5° to -2° and stirred an addnl. 30 min., gives 65% of the Ac derivative, decompose violently at 193°, of 2-nitramino-6-aminopyridine (VIII), darkens at 240-50° (hydrolysis by refluxing 1 h. with N NaOH); reduction of 15.4 g. VIII in 300 cc. 10% NaOH at 0-2° with 31 g. Zn gives 69% 2-hydrazino-6-aminopyridine, pale yellow, m. 93-4°; warmed 2 h. on the steam bath with AcCH2CO2Et (N atm.), there results 44% 1- (6-amino-2-pyridyl)-3-methyl-5-pyrazolone, m. 188-9.5°. 3-Methylpyridine (80 g.), 160 g. PhNMe2, and 144 g. NaNH2, heated 10 h. at 130-50° and 6 h. at 170-200°, give 4% 2,6-diamino-3-methylpyridine, m. 149-50°. 2,6-Dihydroxy-4-methylpyridine (9 g.) and 30 g. PBr3, heated 4.5 h. at 180°, give 36% 2,6-dibromo-4-methylpyridine, m. 74-5°; heated with NH4OH (d. 0.9) 27 h. at 195°, there results 71% 2,6-diamino-4-methylpyridine, m. 87-8°, which on sublimation m. 109-11° but reverts to the lower m.p. on standing. 2,6-Diamino-3-iodopyridine (23.5 g.) in 25 cc. AcOH and 35 cc. Ac2O, heated 1 h. on the steam bath, gives 33% of the di-Ac derivative, m. 210-11°. I (38 g.) in 550 cc. H2O, treated with 93 g. iodine and 93 g. KI in 150 cc. H2O, the mixture stirred 8 h., and allowed to stand overnight at room temperature, gives 36% 2,6-diamino-3,5-diiodopyridine-HCl, m. 160-5°; the free base m. 209-10°. 3-Methoxypyridine (IX) (15.8 g.) in 100 cc. concentrated H2SO4, treated dropwise (with cooling) with 25 cc. HNO3 (d. 1.6) and warmed 6 h. on the steam bath, gives 12.2 g. 3-methoxy-2,6-dinitropyridine (X), m. 114-15°. IX (57 g.), added to 130 cc. concentrated H2SO4 at 5°, the mixture treated with 70 cc. HNO3 (d. 1.6), and heated 1 h. on the steam bath, yields 38 g. 2-nitro-3-methoxypyridine (XI), m. 73-5°; 5 g. XI in 15 cc. concentrated H2SO4, treated with 4 cc. HNO3 (d. 1.6), gives 4.4 g. X. Catalytic reduction (Pt oxide) of 16.8 g. X in 500 cc. AcOH and 250 cc. Ac2O at room temperature (4 h.) gives 60% 3-methoxy-2,6-diacetamidopyridine, m. 173.5-4.5°. 2,3,6-Triaminopyridine-2HCl in 200 cc. H2O and 25 g. Ac2 in 200 cc. H2O, boiled 4 min., yield 98% 2,3-dimethyl-6-aminopyrido[2,3]pyrazine, m. 227-8°; 6-aminopyrido[2,3]pyrazine m. 267°, 62%. 2,3,6-Triaminopyridine oxalate (80 g.) in 150 cc. (CO2Et)2, heated 90 min. at 185°, gives 68% 2,3-dihydroxy-6-aminopyrido[2,3]pyrazine, does not m. below 300°. Addition of 23.8 g. 2,6-diacetamido-3-nitropyridine to 100 g. SnCl2.2H2O in 150 cc. concentrated HCl gives 26% 2-methyl-5-amino-1-imidazo[b]pyridine-HCl; neither the base nor the salt melts. I (55 g.) and 194 g. KCNS in 1 l. 95% AcOH, treated dropwise at -5° to -10° with 26 cc. Br, give 24% 2,5-diaminopyrido[2,3-d]thiazole (XII), m. 138-9°; II likewise gives the 5-Ac derivative of XII, m. 184-5°. I (66 g.) in 2 l. AcOH, treated with 460 g. KCNS in 100 cc. H2O and then at 0-3° with 64 cc. Br, with stirring 1 h. at room temperature, yields 22% 2,6-diaminopyrido[2,3-d,6,5-d’]bisthiazole, does not melt below 300°. I (25 g.), 29 g. I.HCl, and 42 g. benzoin, heated 1 h. at 185°, yield 89% 2,3-diphenyl-6-amino-1-pyrrolo[2,3-b]pyridine, m. 234.5-5.5°. 2-Amino-6-(3-keto-1-methylbutylideneamino)pyridine (16 g.) in 100 cc. 85% H3PO4, warmed 1 h. on the steam bath, gives 84% 2,4-dimethyl-7-amino-1,8-naphthyridine, m. 216-18°; this results in 85% yield from 5 g. I and 5 cc. CH2Ac2 in 25 cc. 85% H3PO4 on warming 30 min. on the steam bath. 2,7-Dihydrazino-4-methyl-1,8-naphthyridine-2HCl-2H2O (23 g.) and 18 g. AcCH2CO2Et in 200 cc. 50% EtOH, heated 5 min. at 70°, give 84% 2,7-bis(3-methyl-5-keto-1-pyrazolyl)-4-methyl-1,8-naphthyridine, m. 260-2°. The most active of these compounds (II, XII, and the di-Ac derivative of I) are only 1/3 as active as quinine as antiparasitic agents for Plasmodium lophurae in ducklings. The experimental process involved the reaction of 3-Methylpyridine-2,6-diamine(cas: 51566-22-4).Related Products of 51566-22-4

The Article related to aminopyridines, malaria and other aspects.Related Products of 51566-22-4

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

On April 15, 2013, Wirasorn, Kosin; Ngamprasertchai, Thundon; Chindaprasirt, Jarin; Sookprasert, Aumkhae; Khantikaew, Narong; Pakkhem, Ake; Ungarereevittaya, Piti published an article.Name: N,N-Dimethyl-3-phenyl-3-(pyridin-2-yl)propan-1-amine maleate The title of the article was Prognostic factors in resectable cholangiocarcinoma patients: Carcinoembryonic antigen, lymph node, surgical margin and chemotherapy.. And the article contained the following:

AIM: To evaluate outcomes in resectable cholangiocarcinoma patients and to determine prognostic factors. METHODS: A retrospective study was conducted among newly-diagnosed cholangiocarcinoma patients from January 2009 to December 2011 who underwent curative resection in Srinakarind Hospital (a 1000-bed university hospital). Two hundred and sixty-three cholangiocarcinoma patients with good performance were enrolled. These patients had pathological reports with clear margins or microscopic margins. Prognostic factors which included clinical factors, serum liver function test as well as serum tumor makers at presentation, tumor data, and receiving adjuvant chemotherapy were determined by uni- and multivariate analysis. RESULTS: The median overall survival time was 17 mo (95%CI: 13.2-20.7); and 1-, 2-, and 3- year survival rates were 65.5%, 45.2% and 35.4%. Serum albumin levels, serum carcinoembryonic antigen (CEA) levels, staging classifications by American Joint Committee on cancer, pathological tumor staging, lymph node metastases, tumor grading, surgical margin status, and if adjuvant chemotherapy was administered, were shown to be significant prognostic factors of resectable cholangiocarcinoma by univariate analysis. Multivariate analysis, however, established that only abnormal serum CEA [hazard ratio (HR) 1.68; P = 0.027] and lymph node metastases (HR 2.27; P = 0.007) were significantly associated with a decrease in overall survival, while adjuvant chemotherapy (HR 0.71; P = 0.067) and surgical margin negative (HR 0.72; P = 0.094) tended to improve survival time. CONCLUSION: Serum CEA and lymph node metastases which were associated with advanced stage tumors become strong negative prognostic factors in cholangiocarcinoma. The experimental process involved the reaction of N,N-Dimethyl-3-phenyl-3-(pyridin-2-yl)propan-1-amine maleate(cas: 132-20-7).Name: N,N-Dimethyl-3-phenyl-3-(pyridin-2-yl)propan-1-amine maleate

The Article related to adjuvant, carcinoembryonic antigen, chemotherapy, cholangiocarcinoma, hepatectomy, lymph nodes, neoplasm metastasis, prognosis, surgical margin status, survival rate, and other aspects.Name: N,N-Dimethyl-3-phenyl-3-(pyridin-2-yl)propan-1-amine maleate

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

On January 31, 1979, Nicholson, S. H.; Suckling, C. J.; Iversen, L. L. published an article.HPLC of Formula: 636-73-7 The title of the article was GABA analogs: conformational analysis of effects on [3H]GABA binding to postsynaptic receptors in human cerebellum. And the article contained the following:

A study of the inhibition of Na-independent 3H-labeled GABA [56-12-2] binding to synaptic membranes of human brain cortex by synthesized simple substituted GABA mols. and some related aromatic and heterocyclic amino acids showed that C-alkyl or -aryl substitution of the GABA mol. markedly reduced its ability to bind to the receptor. Rigid mols. were also unable to interact strongly with the receptor. The larger and more numerous the substituents, the weaker was the receptor binding of the GABA analog. For binding to the GABA receptor, the substituent blocked the approach of the charged atom of the ligand to its complementary site on the receptor, and also raised the energy of that conformation required for binding to the receptor. A planar, eclipsed, partially folded conformation must be adopted by GABA when it binds to its receptor. The experimental process involved the reaction of Pyridine-3-sulfonic acid(cas: 636-73-7).HPLC of Formula: 636-73-7

The Article related to gaba receptor structure activity, Pharmacodynamics: Structure-Activity and other aspects.HPLC of Formula: 636-73-7

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

On August 18, 2020, Xia, Yanzhi; Long, Xiaojing; Jiang, Zhenjie; Li, Daohao; Ji, Quan; Quan, Fengyu; Wang, Bingbing published a patent.Recommanded Product: [2,2′-Bipyridine]-3,3′-diamine The title of the patent was Marine organism polysaccharide grafted pyridine organic micromolecule multicolor adjustable aggregation induced luminescent material and preparation method thereof. And the patent contained the following:

The invention relates to polysaccharide grafted pyridine organic micromol., the pyridine mols. are chem. cross-linked through Schiff base reactions to prepare multicolor tunable marine biopolysaccharide materials with aggregation-induced luminescence properties. The experimental process involved the reaction of [2,2′-Bipyridine]-3,3′-diamine(cas: 75449-26-2).Recommanded Product: [2,2′-Bipyridine]-3,3′-diamine

The Article related to polysaccharide grafted pyridine organic luminescent material, Industrial Carbohydrates: Nonsugars and other aspects.Recommanded Product: [2,2′-Bipyridine]-3,3′-diamine

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

On June 1, 2018, Le, Chip; Chen, Tiffany Q.; Liang, Tao; Zhang, Patricia; MacMillan, David W. C. published an article.Synthetic Route of 2229858-27-7 The title of the article was A radical approach to the copper oxidative addition problem: Trifluoromethylation of bromoarenes. And the article contained the following:

Transition metal-catalyzed arene functionalization was widely used for mol. synthesis over the past century. In this arena, copper catalysis has long been considered a privileged platform due to the propensity of high-valent copper to undergo reductive elimination with a wide variety of coupling fragments. However, the sluggish nature of oxidative addition has limited copper’s capacity to broadly facilitate haloarene coupling protocols. Here, this copper oxidative addition problem can be overcome with an aryl radical-capture mechanism, wherein the aryl radical was generated through a silyl radical halogen abstraction. This strategy was applied to a general trifluoromethylation of aryl bromides through dual copper-photoredox catalysis. Mechanistic studies support the formation of an open-shell aryl species. The experimental process involved the reaction of 4,4′-Bis(trifluoromethyl)-2,2′-bipyridinebis[3,5-difluoro-2-[5-methyl-2-pyridinyl)phenyl] iridium(III) hexafluorophosphate(cas: 2229858-27-7).Synthetic Route of 2229858-27-7

The Article related to copper oxidative addition trifluoromethylation bromoarene, Physical Organic Chemistry: General and other aspects.Synthetic Route of 2229858-27-7

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

Kelani, Khadiga M.; Hegazy, Maha A.; Hassan, Amal M.; Tantawy, Mahmoud A. published an article in 2021, the title of the article was Determination of naphazoline HCl, pheniramine maleate and their official impurities in eye drops and biological fluid rabbit aqueous humor by a validated LC-DAD method.COA of Formula: C20H24N2O4 And the article contains the following content:

A simple RP-HPLC-DAD method was developed and validated, as per the ICH guidelines, for simultaneous determination of naphazoline HCl (NPZ) & pheniramine maleate (PHN) along with three of their official impurities. Chromatog. separation was performed on a hypersil ODS column (5 mm, 250-4.6 mm i.d.) with isocratic elution using phosphate buffer pH 6.0: acetonitrile (70 : 30, volume/volume) as mobile phase, at a flow rate of 1.0 mL min-1 and UV detection at 260.0 nm. The developed method was found to be linear over the concentration ranges of 5.00-45.00 Μg mL-1 for NPZ and NPZ impurity B and 10.00-110.00 Μg mL-1, 10-70 Μg mL-1 and 10-120 Μg mL-1 for PHN, and PHN impurity A and B, resp., with correlation coefficient values <0.999 for the five cited compounds The method was confirmed to be accurate, robust and precise with RSD >2.0%. LOD and LOQ values for the five cited compounds were calculated Moreover, the method was also validated in rabbit aqueous humor as per the US food and drug administration (FDA) bioanal. validation guidelines. Finally, the proposed method was applied for the anal. of the two drugs along with their impurities in dosage form and spiked aqueous humor samples. The experimental process involved the reaction of N,N-Dimethyl-3-phenyl-3-(pyridin-2-yl)propan-1-amine maleate(cas: 132-20-7).COA of Formula: C20H24N2O4

The Article related to naphazoline hcl pheniramine maleate eye drop biol fluid, Biochemical Methods: Immunological and other aspects.COA of Formula: C20H24N2O4

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

Madura, J. D.; Lombardini, J. B.; Briggs, J. M.; Minor, D. L.; Wierzbicki, A. published an article in 1997, the title of the article was Physical and structural properties of taurine and taurine analogs.Formula: C5H5NO3S And the article contains the following content:

The inhibition of the phosphorylation of an ∼20kDa protein present in the mitochondrial fraction of the rat retina by taurine and taurine analogs was investigated using computational methods. Correlations between mol. weight, mol. volume, and calculated pKa values vs. IC50 values are reported. These data appear to support the hypotheses according to Lombardini and Props that the inhibition of the phosphorylation of an ∼20 kDa protein by taurine and taurine analogs dependent on (i) the critical distance between the N and S atoms in the taurine moiety (S-C-C-N) of the analog, (ii) the environment of the N atom in the taurine analog (saturated ring vs. unsaturated ring), and (iii) the placement of both the S and N atoms not being present simultaneously in the ring structure. Using computational methods results supporting hypotheses (i) and (ii) are presented. The experimental process involved the reaction of Pyridine-3-sulfonic acid(cas: 636-73-7).Formula: C5H5NO3S

The Article related to taurine qsar protein phosphorylation inhibition retina, Mammalian Biochemistry: Metabolism and other aspects.Formula: C5H5NO3S

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

Kawata, Tsutomu; Yamamoto, Motokazu; Yamana, Masao; Tajima, Moritaka; Nakano, Tomoyasu published an article in 1975, the title of the article was Characteristics of viologen derivatives for electrochromic display.Recommanded Product: 1,1′-Dipropyl-[4,4′-bipyridine]-1,1′-diium bromide And the article contains the following content:

The polarog. half-wave potentials (E1/2, in aqueous solutions with pH 3.29 at 25°) and the absorption spectra (at λ = 250-700 nm) in various media (aqueous solution, MeOH, glycerin) were determined to characterize the electrochromic behavior of the viologen derivatives X-RN+C5H4-C5H4N+RX- [= Viol] (R = Pr, C6H13, or C7H15 for X = Br; X = Cl, Br, or I for R = PhCH2). Two polarog. waves were observed for each derivative: the 1st E1/2 [= 0.568-0.710 V vs. SCE] was attributed to the reduction, dication of Viol (I, colorless) + e- ⇄ radical cation (II, colored); and the 2nd E1/2 [= 0.775-0.965 V] was attributed to II + e- ⇄ biradical (III, colored). The E1/2 values were smaller for the PhCH2 derivatives than for the alkyl derivatives For R = PhCH2, the observed absorption maximum were at λ (in nm) ≈ 260 for I, ≈ 260, 400, and 630 for II, and ≈ 380 for III. With a viologen derivative in an electrochromic display device (having a transparent SnO2 cathode and a Pt anode), the writing time decreased with increasing applied voltage, and was ∼0.4-0.8 sec for obtaining a transmittance of 80%. An applied voltage greater than the 2nd E1/2 caused the color to change from purple to yellow; on open circuit, the color changed back to purple. The experimental process involved the reaction of 1,1′-Dipropyl-[4,4′-bipyridine]-1,1′-diium bromide(cas: 52243-87-5).Recommanded Product: 1,1′-Dipropyl-[4,4′-bipyridine]-1,1′-diium bromide

The Article related to viologen derivative polarog optical absorption, electrochromic display viologen derivative, Electric Phenomena: Other Devices and other aspects.Recommanded Product: 1,1′-Dipropyl-[4,4′-bipyridine]-1,1′-diium bromide

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

On May 11, 2017, Gunaga, Prashantha; Lloyd, John; Mummadi, Somanadham; Banerjee, Abhisek; Dhondi, Naveen Kumar; Hennan, James; Subray, Veena; Jayaram, Ramya; Rajugowda, Nagendra; Umamaheshwar Reddy, Kommuri; Kumaraguru, Duraimurugan; Mandal, Umasankar; Beldona, Dasthagiri; Adisechen, Ashok Kumar; Yadav, Navnath; Warrier, Jayakumar; Johnson, James A.; Sale, Harinath; Putlur, Siva Prasad; Saxena, Ajay; Chimalakonda, Anjaneya; Mandlekar, Sandhya; Conder, MaryLee; Xing, Dezhi; Gupta, Arun Kumar; Gupta, Anuradha; Rampulla, Richard; Mathur, Arvind; Levesque, Paul; Wexler, Ruth R.; Finlay, Heather J. published an article.Name: Pyridine-3-sulfonic acid The title of the article was Selective IKur Inhibitors for the Potential Treatment of Atrial Fibrillation: Optimization of the Phenyl Quinazoline Series Leading to Clinical Candidate 5-[5-Phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl]pyridine-3-sulfonamide. And the article contained the following:

We have recently disclosed 5-phenyl-N-(pyridin-2-ylmethyl)-2-(pyrimidin-5-yl)quinazolin-4-amine (I) as a potent IKur current blocker with selectivity vs. hERG, Na and Ca channels and an acceptable preclin. PK profile. On further characterization in vivo, Compound I demonstrated an unacceptable level of brain penetration. In an effort to reduce the level of brain penetration while maintaining the overall profile, SAR was developed at the C2′ position for a series of close analogs by employing hydrogen bond donors. As a result, 5-(5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl)pyridine-3-sulfonamide (II) was identified as the lead compound in this series. Compound II showed robust effects in rabbit and canine pharmacodynamic models and an acceptable cross-species pharmacokinetic profile and was advanced as the clin. candidate. Further optimization of II to mitigate pH dependent absorption resulted in identification of the corresponding phosphoramide prodrug (29) with an improved solubility and pharmacokinetic profile. The experimental process involved the reaction of Pyridine-3-sulfonic acid(cas: 636-73-7).Name: Pyridine-3-sulfonic acid

The Article related to ph quinazoline sulfonamide synthesis pharmacokinetics brain potassium channel herg, pyridine sulfonamide antiarrhythmic atrial fibrillation, Pharmacology: Structure-Activity and other aspects.Name: Pyridine-3-sulfonic acid

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

On November 19, 1998, Liu, Shenquan; Tang, Cheng; Ho, Bin; Ankersen, Michael; Stidsen, Carsten E.; Crider, A. Michael published an article.Synthetic Route of 199522-66-2 The title of the article was Nonpeptide Somatostatin Agonists with sst4 Selectivity: Synthesis and Structure-Activity Relationships of Thioureas. And the article contained the following:

Utilizing NNC 26-9100 as a structural lead, a variety of nonpeptide derivatives of somatostatin were synthesized and evaluated for sst2 and sst4 receptor binding affinity. A novel thiourea scaffold was utilized to attach (1) a heteroaromatic nucleus to mimic the Trp8 residue, (2) a nonheteroarom. nucleus to mimic Phe7, and (3) a primary amine or other basic group to mimic the Lys9 residue of somatostatin. Displacement studies were carried out using membranes from cell lines expressing ssts [BHK cells (sst4) and HEK 293 cells (sst2)] utilizing [125I]Tyr11-SRIF as the radioligand. Several thioureas and an urea derivative exhibited Ki values of less than 100 nM. Two thioureas and the urea derivative are believed to be the most potent nonpeptide sst4 agonists known with Ki of 6, 16, and 14 nM, resp. Since the thiourea and the urea derivatives exhibit high sst4 selectivity, these novel nonpeptide derivatives may be useful tools for studying the sst4 receptor. Studies are currently in progress to evaluate the therapeutic potential of NNC 26-9100 in the treatment of glaucoma. The experimental process involved the reaction of N1-(5-Bromopyrid-2-yl)ethane-1,2-diamine(cas: 199522-66-2).Synthetic Route of 199522-66-2

The Article related to thiourea preparation structure somatostatin agonist, nnc26910 derivative somatostatin sst4 receptor agonist, Pharmacology: Structure-Activity and other aspects.Synthetic Route of 199522-66-2

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem